OABI Stock Overview
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OmniAb, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.59 |
| 52 Week High | US$6.72 |
| 52 Week Low | US$3.14 |
| Beta | 0 |
| 1 Month Change | -12.90% |
| 3 Month Change | -23.37% |
| 1 Year Change | 27.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.66% |
Recent News & Updates
Recent updates
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Mar 26
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
Feb 28OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 15Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
Nov 11Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
Aug 13OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
May 14Shareholder Returns
| OABI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -11.7% | -5.9% | -3.7% |
| 1Y | 27.9% | -5.5% | 20.2% |
Return vs Industry: OABI exceeded the US Life Sciences industry which returned -4.3% over the past year.
Return vs Market: OABI exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| OABI volatility | |
|---|---|
| OABI Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OABI's share price has been volatile over the past 3 months.
Volatility Over Time: OABI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 106 | Matt Foehr | www.omniab.com |
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company’s technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners’ drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
OmniAb, Inc. Fundamentals Summary
| OABI fundamental statistics | |
|---|---|
| Market cap | US$537.61m |
| Earnings (TTM) | -US$50.62m |
| Revenue (TTM) | US$34.16m |
15.7x
P/S Ratio-10.6x
P/E RatioIs OABI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OABI income statement (TTM) | |
|---|---|
| Revenue | US$34.16m |
| Cost of Revenue | US$0 |
| Gross Profit | US$34.16m |
| Other Expenses | US$84.78m |
| Earnings | -US$50.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -148.16% |
| Debt/Equity Ratio | 0% |
How did OABI perform over the long term?
See historical performance and comparison